Temporal neuropathologic and behavioral phenotype of 6 neo/6 neo Pompe pisease mice

Journal of Neuropathology and Experimental Neurology

Volumn 67, Issue 8, 2008, Pages 803-818

  Sidman, Richard L ^a,e   Taksir, Tatyana ^b   Fidler, Jonathan ^b   Zhao, Michael ^b   Dodge, James C ^b   Passini, Marco A ^b   Raben, Nina ^c,d   Thurberg, Beth L ^b   Cheng, Seng H ^b   Shihabuddin, Lamya S ^b  

^a Department of Neurology ^*  (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c GENZYME CORPORATION   (United States)

^d NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^e HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

Axon terminal degeneration; Genetic disease; Glycogen storage in CNS; Lysosomal storage diseases; Neurobiology

Indexed keywords

GLYCOGEN; ALPHA GLUCOSIDASE; GLIAL FIBRILLARY ACIDIC PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BRAIN CORTEX; BRAIN NERVE CELL; BRAIN STEM; CELL TYPE; CENTRAL NERVOUS SYSTEM; CEREBELLUM NUCLEUS; CERVICAL SPINAL CORD; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; FEMALE; GLIA; GLYCOGEN STORAGE DISEASE TYPE 2; MALE; MENINX; MOTONEURON NUCLEUS; MOUSE; MUSCLE FUNCTION; MUSCLE STRENGTH; NERVE DEGENERATION; NERVE ENDING; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; NONHUMAN; OLFACTORY BULB; PHENOTYPE; PRIORITY JOURNAL; PURKINJE CELL; PYRAMIDAL NERVE CELL; RHOMBENCEPHALON; ROTAROD TEST; SENSORY GANGLION; SENSORY NERVE CELL; SPINAL CORD; SPINAL CORD NERVE CELL; SPINAL GANGLION; STAINING; THALAMUS; WHITE MATTER; AGE; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; DISEASE MODEL; GENETICS; METABOLISM; METHODOLOGY; MOTOR ACTIVITY; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOMOTOR PERFORMANCE; REACTION TIME; SKELETAL MUSCLE; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

AGE FACTORS; ALPHA-GLUCOSIDASES; ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOGEN; GLYCOGEN STORAGE DISEASE TYPE II; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, ELECTRON, TRANSMISSION; MOTOR ACTIVITY; MUSCLE STRENGTH; MUSCLE, SKELETAL; PHENOTYPE; PSYCHOMOTOR PERFORMANCE; REACTION TIME;

EID: 52249123294     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3181815994     Document Type: Article

References (61)

1. Pompe JC. Over idiopathische hypertrophie van het hart. Ned Tijdschr Geneeskd 1932;76:304-11
2. Hirshhorn R, Reuser A. Glycogen storage disease type II: Acid alpha-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill, 2001:3389-420
3. Cori GT. Glycogen structure and enzyme deficiencies in glycogen storage disease. Harvey Lect 1954;8:145-71
4. Hers HG. Alpha-glucosidase deficiency in generalized glycogen storage disease (Pompe's disease). Biochem J 1963;86:11-16
5. Reuser AJ, Drost MR. Lysosomal dysfunction, cellular pathology and clinical symptoms: Basic principles. Acta Paediatr Suppl 2006;95:77-82
6. Bijvoet AG, Kroos MA, Pieper FR, et al. Recombinant human acid alpha-glucosidase: High level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice. Hum Mol Genet 1998;7:1815-24
7. Hirschhorn R. Glycogen storage disease type II (GSDII). In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease, 7th ed, Vol 2. New York, NY: McGraw-Hill, 1995: 2443-65
8. Kishnani PS, Hwu W-L, Mandel H, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006;148:671-76
9. Pellegrini N, Laforet P, Orlikowski D, et al. Respiratory insufficiency and limb muscle weakness in adults with Pompe's disease. Eur Respir J 2005;26:1024-31
10. Hagemans MLC, Hop WJC, Van Doorn PA, et al. Course of disability and respiratory function in untreated late-onset Pompe disease. Neurology 2006;66:581-83
11. Crome L, Cumings JN, Duckett S. Neuropathological and neurochemical aspects of generalized glycogen storage disease. J Neurol Neurosurg Psychiatry 1963;26:422-30
12. Mancall EL, Aponte GE, Berry RG. Pompe's disease (diffuse glycogenosis) with neuronal storage. J Neuropathol Exp Neurol 1965;24:85-96
13. Gambetti P, DiMauro S, Baker L. Nervous system in Pompe's disease. Ultrastructure and biochemistry. J Neuropathol Exp Neurol 1971;30: 412-30
14. Martin JJ, de Barsy T, van Hoof F, et al. Pompe's disease: An inborn lysosomal disorder with storage of glycogen. A study of brain and striated muscle. Acta Neuropathol (Berl) 1973;23:229-44
15. Engel AG, Gomez MR, Seybold ME, et al. The spectrum and diagnosis of acid maltase deficiency. Neurol 1973;23:95-106
16. Martini C, Ciana G, Benettoni A, et al. Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2. Neurol 2001;57: 906-8
17. Thurberg GBL, Maloney CL, Vaccaro C, et al. Characterization of preand post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 2006;86:1208-20
18. Slonim AE, Coleman RA, McElligot MA, et al. Improvement of muscle function in acid maltase deficiency by high-protein therapy. Neurol 1983;33:34-8
19. Umpleby AM, Trend PS, Chubb D, et al. The effect of a high protein diet on leucine and alanine turnover in acid maltase deficiency. J Neurol Neurosurg Psychiatry 1989;52:954-61
20. Teng YT, Su WJ, Hou JW, et al. Infantile-onset glycogen storage disease type II (Pompe disease): Report of a case with genetic diagnosis and pathological findings. Chang Gung Med J 2004;27:379-84
21. Van den Hout H, Reuser AJ, Vulto AG, et al. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000;356: 397-98
22. van der Beek NA, Hagemans ML, van der Ploeg AT, et al. Pompe disease (glycogen storage disease type II): Clinical features and enzyme replacement therapy. Acta Neurol Belg 2006;106:82-86
23. Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid a-glucosidase. Neurol 2007;68:99-109
24. Bijvoet AG, van de Kamp EH, Kroos MA, et al. Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease. Hum Mol Genet 1998;7:53-62
25. Raben N, Nagaraju K, Lee E, et al. Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem 1998;273:19086-92
26. Bijvoet AG, Van Hirtum H, Vermey M, et al. Pathological features of glycogen storage disease type II highlighted in the knockout mouse model. J Pathol 1999;189:416-24
27. Lynch C, Johnson J, Vaccaro C, et al. High-resolution light microscopy (HRLM) and digital analysis of Pompe disease pathology. J Histochem Cytochem 2005;53:63-73
28. Taksir TV, Griffiths D, Johnson J, et al. Optimized preservation of CNS morphology for the identification of glycogen in the Pompe mouse model. J Histochem Cytochem 2007;55:991-98
29. Fix AS, Ross JF, Stitzel SR, et al. Integrated evaluation of central nervous system lesions: Stains for neurons, astrocytes, and microglia reveal the spatial and temporal features of MK-801-induced neuronal necrosis in the rat cerebral cortex. Toxicol Pathol 1996;24:291-304
30. Colman JR, Nowocin KJ, Switzer RC, et al. Mapping and reconstruction of domoic acidYinduced neurodegeneration in the mouse brain. Neurotoxicol Teratol 2005;27:753-67
31. Carlsen J, De Olmos JS. A modified cupric-silver technique for the impregnation of degenerating neurons and their processes. Br Res 1981; 208:426-31
32. de Olmos JS, Beltramino CA, de Olmos de Lorenzo S. Use of an amino-cupric-silver technique for the detection of early and semiacute neuronal degeneration caused by neurotoxicants, hypoxia, and physical trauma. Neurotoxicol Teratol 1994;16:545-61
33. Schmued LC, Stowerts CC, Scallet AC, et al. Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. Br Res 2005;1035:24-31
34. Bian G-L, Wei L-C, Shi M, et al. Fluoro-Jade C can specifically stain the degenerative neurons in the substantia nigra of the 1-methyl-4- phenyl-1,2,3,6-tetrahydro pyridineYtreated C57BL/6 mice. Br Res 2007;1150:55-61
35. Doetsch F, Caille I, Lim DA, et al. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 1999;97:703-16
36. Alvarez-Buylla A, Garcia-Verdugo JM, Tramontin AD. A unified hypothesis on the lineage of neural stem cells. Nat Rev Neurosci 2001; 2:287-93
37. Zhao M, Choi Y-S, Obrietan K, et al. Synaptic plasticity (and the lack thereof) in hippocampal CA2 neurons. J Neurosci 2007;27:12025-32
38. Fukuda T, Ewan L, Bauer M, et al. Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann Neurol 2006; 59:700-8
39. Fukuda T, Roberts A, Plotz PH, et al. Acid alpha-glucosidase deficiency (Pompe disease). Curr Neurol Neurosci Rep 2007;7:71-77
40. Hagemans ML, van Schie SP, Janssens AC, et al. Fatigue: An important feature of late-onset Pompe disease. J Neurol 2007;254:941-45
41. Nemes A, Soliman OI, Geleijnse ML, et al. Increased aortic stiffness in glycogenosis type 2 (Pompe's disease). Int J Cardiol 2007;120: 138-41
42. Braunsdorf WE. Fusiform aneurysm of basilar artery and ectatic internal carotid arteries associated with glycogenosis type 2 (Pompe's disease). Neurosurg 1987;21:748-49
43. Healy PJ, Nicholls PJ, Martiniuk F, et al. Evidence of molecular heterogeneity for generalised glycogenosis between and within breeds of cattle. Aust Vet J 1995;72:309-11
44. Walvoort HC, Dormans JA, van den Ingh TS. Comparative pathology of the canine model of glycogen storage disease type II (Pompe's disease). J Inherit Metab Dis 1985;8:38-46
45. Miyagawa-Tomita S, Morishima M, Nakazawa M, et al. Pathological study of Japanese quail embryo with acid alpha-glucosidase deficiency during early development. Acta Neuropath 1996;92: 249-54
46. Kamphoven JH, de Ruiter MM, Winkel LP, et al. Hearing loss in infantile Pompe's disease and determination of underlying pathology in the knockout mouse. Neurobiol Dis 2004;16:14-20
47. Toussaint D, Danis P. Ocular histopathology in generalized glycogenosis (Pompe's disease). Arch Ophthalmol 1965;73:342-49
48. Goebel HH, Kohlschütter A, Pilz H. Ultrastructural observations on the retina in type II glycogenosis (Pompe's disease). Ophthalmologica 1978; 176:61-68
49. Araoz C, Sun CN, Shenefelt R, et al. Glycogenosis type II (Pompe's disease): Ultrastructure of peripheral nerves. Neurology 1974;24: 739-42
50. Origuchi Y, Itai Y, Matsumoto S, et al. Quantitative histological study of the sural nerve in a child with acid maltase deficiency (glycogenosis type II). Pediatr Neurol 1986;2:346-49
51. Schoser BG, Muller-Hocker J, Horvath R, et al. Adult-onset glycogen storage disease type 2: Clinico-pathological phenotype revisited. Neuropathol Appl Neurobiol 2007;33:544-59
52. Brown AM, Ransom BR. Astrocyte glycogen and brain energy metabolism. Glia 2007;55:1263-71
53. Van den Hout JM, Kamphoven JH, Winkel LP, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004;113:448-57
54. Hagemans MLC, Winkel LPF, Van Doorn PA, et al. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 2005;128:671-77
55. Winkel LPF, Hagemans MLC, van Doorn PA, et al. The natural course of non-classic Pompe's disease: A review of 225 published cases. J Neurol 2005;252:875-84
56. Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial. Genet Med 2001;3:132-38
57. Cook AL, Kishnani PS, Carboni MP, et al. Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alphaglucosidase enzyme replacement therapy for Pompe disease. Genet Med 2006;8:313-17
58. Winkel LP, Van den Hout JM, Kamphoven JH, et al. Enzyme replacement therapy in late-onset Pompe's disease: A three-year follow-up. Ann Neurol 2004;55:495-502
59. Klinge L, Straub V, Neudorf U, et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: Results of a phase II clinical trial. Neuromuscul Disord 2005;15:24-31
60. Rossi M, Parenti G, Della Casa R, et al. Long-term enzyme replacement therapy for Pompe disease with recombinant human a-glucosidase derived from Chinese hamster ovary cells. J Child Neurol 2007;22: 565-73
61. Brady RO. Enzyme replacement for lysosomal diseases. Annu Rev Med 2006;57:283-96